Cree Files LED Patent Infringement Lawsuit Against BridgeLux

Cree, Inc., a leader in LED solid-state lighting components, today announced that it has filed suit against BridgeLux, Inc. (formerly eLite Optoelectronics) for infringement of U.S. Patent Nos. 6,657,236 (“the ‘236 patent”) and 5,686,738 (“the ‘738 patent”). The suit, which was filed in the U.S. District Court for the Middle District of North Carolina, seeks monetary damages and injunctive relief to prohibit BridgeLux from infringing these patents.

Cree’s ‘236 patent, entitled “Enhanced Light Extraction in LEDs through the Use of Internal and External Optical Elements,” relates to light extraction structures used in LEDs. The ‘738 patent, entitled “Highly Insulating Monocrystalline Gallium Nitride Thin Films,” relates to semiconductor devices manufactured using a gallium nitride-based buffer technology. The ‘738 patent is owned by the Trustees of Boston University and licensed to Cree on an exclusive basis. Boston University is a co-plaintiff in the suit. The ‘738 patent was also the subject of two prior suits brought by Cree and Boston University against Nichia Corporation and AXT, Inc., both of which resulted in settlements.

“Cree’s leadership in LED technology is the result of significant investment in R&D and our patent portfolio over the last nineteen years. The filing of this suit demonstrates Cree's willingness to protect our R&D investments and patent rights, especially at a time when some segments of the LED marketplace act as if there are no issues with intellectual property,” stated Cree chairman and CEO Charles Swoboda.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.